Volume s1-30, Issue 5
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645


Summary and Conclusions

  • 1.  Ninety-four cases of chronic intestinal amebiasis were treated with Milibis® (bismuthoxy p-N-glycolylarsanilate (Wia, Win 1011)) and/or chiniofon, alone or in combination with bismuth subgallate. Sixteen of the patients who relapsed after the first courses of treatment were given a second course of treatment with Milibis®, bringing the total number of treatments to 106.
  • 2.  The patients who were freed of were followed up for an average period of 287 days (range 35 to 543 days, median 344 days). During this period of observation, an average of 10 post-treatment stool specimens per patient were examined.
  • 3.  In thirty-two cases chiniofon was used as the principal amebacide. It was used either alone, or with, or alternately with bismuth subgallate. Of the thirty-two cases thus treated fifteen (47 per cent) were cleared of their amebas, and seventeen (53 per cent) relapsed.
  • 4.  Milibis® alone, or in combination with chiniofon and/or bismuth subgallate was given to seventy-two persons; sixty-four (89 per cent) of these were immediately cleared of . Sixty-two (93 per cent) of sixty-seven cases in which chiniofon was not a complicating factor were cleared of for an average observation period of 320 days (median, 433 days).
  • 5.  Milibis® also affected other intestinal protozoa. Sixteen of eighteen cases (90 per cent) of infections; twenty-three of forty-nine (47 per cent) cases of infections and twelve of twenty-nine (41 per cent) cases of infections were cleared. Milibis® had very little effect on the flagellate , but it eliminated from the three cases observed.
  • 6.  The clinical efficacy of Milibis® in the treatment of chronic intestinal amebiasis was confirmed; all of six severe cases which had been resistant to other therapy were cleared with a single course of Milibis®.
  • 7.  Milibis® is easy to administer. Treatment does not require hospitalization or confinement to bed. None of the patients treated showed any toxic symptoms or manifestations of intolerance.


Article metrics loading...

The graphs shown below represent data from March 2017
Loading full text...

Full text loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error